NUVB insider plans sale of 200,000 shares valued at $1.43M

NUVB Form 144 shows a planned insider sale of common stock.

Accepted by SEC EDGAR 11/19/2025 - 04:09 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

NUVB Form 144 shows a planned insider sale of common stock. A holder has filed notice to sell 200,000 shares of Nuvation Bio common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,427,680.00. The shares are listed for sale on the NYSE with an approximate sale date of 11/19/2025. As of the filing, 342,833,433 shares of Nuvation Bio common stock were outstanding, which is a baseline figure for the company’s equity. The shares to be sold were acquired on 11/19/2025 by exercising stock options under a registered plan and paid for in cash.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Nuvation Bio's (NUVB) latest Form 144 filing disclose?

The Form 144 filing for NUVB discloses a planned sale of 200,000 shares of Nuvation Bio common stock by a holder, using Morgan Stanley Smith Barney LLC as broker, with an approximate aggregate market value of $1,427,680.00.

How many Nuvation Bio (NUVB) shares are planned to be sold and on which exchange?

The notice covers the proposed sale of 200,000 common shares of Nuvation Bio on the NYSE, with an approximate sale date of 11/19/2025.

How were the Nuvation Bio (NUVB) shares in the Form 144 acquired?

The 200,000 Nuvation Bio common shares were acquired on 11/19/2025 through the exercise of options under a registered plan, and the exercise was paid in cash.

What is the aggregate market value of the NUVB shares to be sold under this Form 144?

The filing reports an aggregate market value of $1,427,680.00 for the 200,000 Nuvation Bio common shares that are planned to be sold.

How many Nuvation Bio (NUVB) shares are outstanding in this Form 144 disclosure?

The Form 144 indicates that 342,833,433 common shares of Nuvation Bio were outstanding, providing a baseline context for the company’s total equity.

Which broker is handling the proposed Nuvation Bio (NUVB) share sale in the Form 144?

The proposed sale of Nuvation Bio common stock is listed to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001865826
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	NUVATION BIO INC.
SEC File Number	001-39351
Address of Issuer	1500 Broadway Suite 1401 New York NEW YORK 10036
Phone	332-208-6102
Name of Person for Whose Account the Securities are To Be Sold	DAVID HANLEY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	200000	1427680.00	342833433	11/19/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/19/2025	Exercise of options under a registered plan	Issuer			200000	11/19/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/19/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ David Hanley
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)